-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Structure Therapeutics, Raises Price Target to $125

Benzinga·12/12/2025 17:13:25
語音播報
Morgan Stanley analyst Terence Flynn maintains Structure Therapeutics (NASDAQ:GPCR) with a Overweight and raises the price target from $120 to $125.